Biomerieux SA Cash Flow Conversion Efficiency
Biomerieux SA cash flow conversion efficiency. Based on the latest financial reports, Biomerieux SA (BIM) has a cash flow conversion efficiency ratio of 0.115x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€470.80 Million ≈ $550.41 Million USD) by net assets (€4.11 Billion ≈ $4.80 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biomerieux SA (2005–2025)
Cash flow conversion efficiency of Biomerieux SA from 2005 to 2025. This chart illustrates how Biomerieux SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Biomerieux SA stock quote for real-time trading data and today's change.
Biomerieux SA Cash Flow Conversion Ratio Explained
Biomerieux SA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biomerieux SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomerieux SA ranked by their cash flow conversion efficiency. Also see Biomerieux SA (BIM) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UNICHARM CORP. SP.ADR 1
F:UN41
|
0.047x |
|
Primerica Inc
NYSE:PRI
|
0.062x |
|
RHB Bank Bhd
KLSE:1066
|
0.060x |
|
Orion Oyj B
HE:ORNBV
|
0.086x |
|
Alpha Services and Holdings S.A.
AT:ALPHA
|
0.143x |
|
Westlake Chemical Corporation
NYSE:WLK
|
0.035x |
|
Agree Realty Corporation
NYSE:ADC
|
0.023x |
|
Aker ASA
OL:AKER
|
0.059x |
Annual Cash Flow Conversion Efficiency for Biomerieux SA (2005–2025)
The table below shows the annual cash flow conversion efficiency of Biomerieux SA from 2005 to 2025. Review how much free cash does Biomerieux SA generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.11 Billion ≈ $4.80 Billion |
€788.30 Million ≈ $921.61 Million |
0.192x | +21.15% |
| 2024-12-31 | €4.21 Billion ≈ $4.92 Billion |
€667.30 Million ≈ $780.14 Million |
0.158x | +33.50% |
| 2023-12-31 | €3.75 Billion ≈ $4.39 Billion |
€445.40 Million ≈ $520.72 Million |
0.119x | -8.98% |
| 2022-12-31 | €3.64 Billion ≈ $4.26 Billion |
€475.10 Million ≈ $555.44 Million |
0.130x | -49.13% |
| 2021-12-31 | €3.16 Billion ≈ $3.70 Billion |
€811.10 Million ≈ $948.26 Million |
0.256x | +9.16% |
| 2020-12-31 | €2.48 Billion ≈ $2.90 Billion |
€582.80 Million ≈ $681.35 Million |
0.235x | +29.82% |
| 2019-12-31 | €2.25 Billion ≈ $2.64 Billion |
€407.90 Million ≈ $476.88 Million |
0.181x | -9.40% |
| 2018-12-31 | €2.00 Billion ≈ $2.34 Billion |
€399.80 Million ≈ $467.41 Million |
0.200x | +1.62% |
| 2017-12-31 | €1.74 Billion ≈ $2.03 Billion |
€341.30 Million ≈ $399.02 Million |
0.197x | -5.06% |
| 2016-12-31 | €1.62 Billion ≈ $1.90 Billion |
€335.60 Million ≈ $392.35 Million |
0.207x | +0.33% |
| 2015-12-31 | €1.50 Billion ≈ $1.76 Billion |
€310.00 Million ≈ $362.42 Million |
0.206x | -3.96% |
| 2014-12-31 | €1.39 Billion ≈ $1.62 Billion |
€298.30 Million ≈ $348.74 Million |
0.215x | +13.19% |
| 2013-12-31 | €1.27 Billion ≈ $1.48 Billion |
€240.50 Million ≈ $281.17 Million |
0.190x | -11.89% |
| 2012-12-31 | €1.20 Billion ≈ $1.40 Billion |
€258.50 Million ≈ $302.21 Million |
0.215x | +9.72% |
| 2011-12-31 | €1.10 Billion ≈ $1.29 Billion |
€216.60 Million ≈ $253.23 Million |
0.196x | -3.71% |
| 2010-12-31 | €976.10 Million ≈ $1.14 Billion |
€199.00 Million ≈ $232.65 Million |
0.204x | -12.83% |
| 2009-12-31 | €806.40 Million ≈ $942.77 Million |
€188.60 Million ≈ $220.49 Million |
0.234x | -18.64% |
| 2008-12-31 | €688.40 Million ≈ $804.81 Million |
€197.90 Million ≈ $231.37 Million |
0.287x | -8.39% |
| 2007-12-31 | €601.30 Million ≈ $702.98 Million |
€188.70 Million ≈ $220.61 Million |
0.314x | +40.41% |
| 2006-12-31 | €557.50 Million ≈ $651.78 Million |
€124.60 Million ≈ $145.67 Million |
0.223x | -32.27% |
| 2005-12-31 | €498.50 Million ≈ $582.80 Million |
€164.50 Million ≈ $192.32 Million |
0.330x | -- |
About Biomerieux SA
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; … Read more